Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05532046
Other study ID # 20623
Secondary ID 2021-005751-36
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 20, 2022
Est. completion date March 31, 2023

Study information

Verified date March 2024
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are looking for a better way to treat people who have chronic heart failure. Chronic heart failure is a medical condition with shortness of breath, tiredness and ankle swelling in which the heart does not pump blood as well as it should. BAY2413555 is a new compound which is under development for the treatment of heart failure. Heart failure is a serious disease in which the heart pumps less well. BAY2413555 is expected to protect the heart and improve cardiac function. The main purpose of this study is to learn how safe BAY2413555 is compared to placebo in participants with chronic heart failure and implanted cardiac defibrillator, or cardiac resynchronization devices (ICD/CRT). A placebo is a treatment that looks like a medicine, but does not have any medicine in it. ICD/CRT are machines placed in the body that use an electric shock/impulse to reset the heart or get it beating correctly. To study the safety, the researchers will record all medical problems the participants may have during the study after starting the study treatment. Medical problems that happen after the participants have started their treatment are also known as "treatment emergent adverse events" (TEAEs). The TEAEs will be compared between participants who received BAY2413555 and those who received placebo. The second purpose of this study is to learn whether BAY2413555 effects electrical signals inside the heart compared to placebo. The study has two parts, A and B. Each part will last for two weeks. In part A, the participants will be assigned by chance to either take BAY2413555 as a tablet by mouth once per day or a placebo. Participants from part A who do not need to stop the study based on predefined criteria continue in part B. They will be assigned by chance to receive either the same dose of BAY2413555 as in part A or a higher dose. Participants who have taken placebo in part A will as well be assigned in part B. Each participant will be in the study for approximately 90 days (including the screening period and follow-up period). In the study, participants will take study medication for 28 days. 8 visits to the study site and 1 telephone contact visit are planned. During the study, the study team will: - do physical examinations - check vital signs - examine heart health using ECG - check the participants' ICD/CRT information - take exercise testing - take blood and urine samples - ask the participants questions about how they are feeling about their quality of life - ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the study treatments or a study procedure. Participants will be closely monitored during the entire study duration and site personnel will take action to mitigate any negative effect, if any, as appropriate. About 30 days after the participants take their last treatment, the study doctors and their team will check the participants' health.


Recruitment information / eligibility

Status Terminated
Enrollment 22
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria: - Providing signed informed consent - Diagnosis of heart failure lasting for at least 3 months, New York Heart Association (NYHA) functional class I-III prior to Visit 1 - Left ventricular ejection fraction (LVEF) = 45% as documented by any imaging modality within the past 12 months prior to Visit 1 - Treatment with Guideline-Directed Medical Therapy Including with mandatory betablocker treatment with either Metoprolol, Carvedilol, Bisoprolol or Nebivolol on stable, highest individually tolerated dose for at least 2 weeks prior to Visit 1 - Implanted cardiac defibrillator (ICD) with pacemaker backup function OR cardiac resynchronization device (CRT) - first implantation at least 3 months prior to Visit 1 Exclusion Criteria: - Permanent atrial fibrillation or other than Sinus rhythm at Visit 1 - History of higher degree atrioventricular (AV) block (Mobitz type II or third-degree AV block) within 4 weeks prior to Visit 1 - Indication for or planned procedure: - Planned cardiac surgery, carotid angioplasty or surgery, transcatheter aortic valve implantation (TAVI) or mitral valve clipping within 3 months starting from the Screening Visit - Percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or implantation of a cardiac resynchronization therapy defibrillator device indicated at Screening or planned within 3 months starting from the Screening Visit - Valvular Disease Repair indicated at Screening or planned within 3 months starting from the Screening Visit. - Occurrence of any of the following within 4 weeks prior to Visit 1: - Myocardial infarction - Stroke or transient ischemic attack (TIA) - coronary artery bypass graft (CABG) - percutaneous coronary intervention (PCI) - Carotid angioplasty - Ablation therapy of atrial fibrillation or other rhythm abnormalities - Heart rate (HR) > 100 bpm at Screening Visit - Restrictive, infiltrative or hypertrophic cardiomyopathy, constrictive pericarditis, acute myocarditis within 3 months prior to Visit 1 - Malignancy of the hematological system within 5 years prior to the Screening Visit - Listed for heart transplantation and/or anticipated implantation of a ventricular assist device at the Screening Visit - Hepatic insufficiency classified as Child-Pugh B or C at the Screening Visit - Estimated (according to the investigator's judgement) inability to perform exercise testing - Any of the following from the blood sample taken at the Screening Visit - Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2 (calculated according to the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) - Hemoglobin < 11 g/dL - White blood cell (WBC) < 3000/mm^3 - Thrombocytes < 100 000/mm^3 - Currently receiving or planned to receive dialysis or ultrafiltration - Chronic obstructive pulmonary disease (COPD) Stage 3 or 4 (GOLD criteria), requiring treatment, or symptomatic asthma requiring current treatment - Prior or concomitant therapy with cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or inducers. Relevant substances need to be discontinued - at least 2 weeks before randomization for CYP3A4 inducers - at least 5 half-lives before randomization for CYP3A4 inhibitors Restarting of these therapies is possible 28 days after last intake of study intervention. This criterion also applies to other inhibitors of CYP3A4, e.g., grapefruit. Prior and concomitant therapy with amiodarone is allowed. - Concomitant treatment with acetylcholine esterase inhibitors within 4 weeks prior to Visit 1 - Use of other investigational drugs. Previous (within 4 weeks, or 5 half-lives of the investigational drug, whichever is longer, prior to Visit 1) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s) - Life expectancy < 6 months at the Screening Visit

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BAY2413555 Dose 1
BAY2413555 Dose 1
BAY2413555 Dose 2
BAY2413555 Dose 2
Placebo to BAY2413555
Placebo to BAY2413555

Locations

Country Name City State
Denmark Capital Region | Gentofte Hospital - Cardiology Research Hellerup
Denmark Odense Universitetshospital, Hjertemedicinsk Amb. Odense C
Denmark Zealand University Hospital | Roskilde - Cardiology Department Roskilde
Germany Pratia | Klinische Forschung Dresden Dresden Sachsen
Israel Barzilai Ashkelon University Medical Center | Cardiology Department Ashkelon
Israel Rambam Health Care Campus | Internal Medicine - Cardiology Department Haifa
Israel Ziv Medical Center | Cardiology Department Zefat
Italy Humanitas Research Hospital | Cardio Center - Clinical, Interventional Cardiology and Coronary Care Milano Lombardia
Italy Fondazione Toscana Gabriele Monasterio | Heart Hospital Gaetano Pasquinucci - Cardiology Department Pisa Toscana
Spain Hospital Alvaro Cunqueiro | Cardiology Department Babio - Beade Pontevedra
Spain Hospital del Mar | Cardiology Department Barcelona
Spain Hospital Universitari de Bellvitge | Bellvitge Biomedical Research Institute - Cardiology Department Barcelona
Spain Junta de Andalucía | University Hospital Reina Sofia - Cardiology Department Córdoba
Spain Hospital Universitario Virgen de la Victoria | Cardiology Department Málaga
Spain Hospital General Universitario de Valencia Valencia
United States Accel Research Sites - Atlanta Clinical Research Center Atlanta Georgia
United States Capital Area Research, LLC Camp Hill Pennsylvania
United States White Oak Medical Center Silver Spring Maryland

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Countries where clinical trial is conducted

United States,  Denmark,  Germany,  Israel,  Italy,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment-emergent adverse events (TEAEs) Up to 56 days
Secondary Number of participants with higher degree atrioventricular (AV) blocks, symptomatic pauses/bradycardia Up to 28 days
Secondary Changes from baseline in resting heart rate (HR) after 2 and 4 weeks of dosing with BAY2413555 Up to 28 days
See also
  Status Clinical Trial Phase
Completed NCT03597646 - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure N/A
Terminated NCT04065997 - Apogee International
Withdrawn NCT03675113 - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure N/A
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Completed NCT02268500 - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) Phase 4
Completed NCT02247245 - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. N/A
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT01919918 - Muscle Afferent Feedback Effects in Patients With Heart Failure Phase 1
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Completed NCT00984529 - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia N/A
Recruiting NCT00863421 - Sleep Disordered Breathing in Patients With Chronic Heart Failure N/A
Completed NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Phase 1
Completed NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study Phase 3
Completed NCT00149409 - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Phase 2/Phase 3
Recruiting NCT04984928 - Readmission Risk of Patients With Heart Failure.
Completed NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05560737 - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I
Not yet recruiting NCT06002321 - Right Ventricular Dysfunction in Chronic Heart Failure